scholarly journals Clinical Effect of Shenfu Injection in Patients with Septic Shock: A Meta-Analysis and Systematic Review

2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
Zijun Mou ◽  
Zhengtao Lv ◽  
Yi Li ◽  
Meng Wang ◽  
Qun Xu ◽  
...  
Keyword(s):  
Heart Rate ◽  
Septic Shock ◽  
Mean Arterial Pressure ◽  
Arterial Pressure ◽  
Conventional Therapy ◽  
Meta Analysis ◽  
Serum Lactate ◽  
Controlled Trials ◽  
Shenfu Injection ◽  
Randomized Controlled

Purpose. To conduct a meta-analysis evaluating the efficacy of Shenfu injection for treating patients with septic shock when compared with conventional therapy.Methods. Eight databases including Pubmed, EMBASE, Cochrane Library, ISI Web of Science, CNKI, Wanfang, VIP, and CBM were searched up to October 2014. Randomized controlled trials assessing the efficacy of Shenfu injection were identified. Mean arterial pressure, heart rate, lactate, and mortality were included as outcome measurements.Results. We analyzed data from 12 randomized controlled trials involving 904 participants. Compared with conventional therapy, Shenfu injection could further increase the mean arterial pressure at 1 hour (SMD 0.38; 95% CI, 0.01–0.74) and 6 hours (SMD 0.82; 95% CI, 0.03–1.61). Shenfu injection could further normalize heart rate at 6 hours (SMD −0.90; 95% CI, −1.47–0.33) and clear serum lactate at 6 hours (SMD −0.51; 95% CI, −0.70–0.32) and 24 hours (SMD, 0.52; 95% CI, −0.77–0.26). As the endpoint of mortality was not unified, it was not meta-analyzed.Conclusions. Based on the findings in present review, Shenfu injection is more effective than conventional therapy in increasing mean arterial pressure, normalizing heart rate, clearing serum lactate, and reducing mortality. These results should be confirmed in higher level clinical trials in the future.

scholarly journals Benefits of esmolol in sepsis and septic shock in adults: a meta-analysis of randomized controlled trials

2021 ◽  
Author(s):  
Chun Chen ◽  
Jing Zhang ◽  
Zemei Zhou
Keyword(s):  
Heart Rate ◽  
Septic Shock ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Volume Index ◽  
Current Evidence ◽  
Controlled Trials ◽  
Central Venous ◽  
Randomized Controlled ◽  
Sepsis And Septic Shock

Abstract Background Sepsis affects millions of people each year, and brings substantial health and economic burden to the global. Esmolol may have the potential in the treatment of sepsis and septic shock in adults. However, current evidence remains controversial. Methods We systematically searched PubMed, EMBASE and the Cochrane Central Register of Controlled Trials from their inception to September 19, 2020 for randomized controlled trials (RCTs) evaluating the efficacy of esmolol in sepsis and septic shock in adults. A random-effects meta-analysis was performed to combine effect estimates. Two investigators independently screened articles, extracted data, and assessed the quality of included studies. Results Seven RCTs were included with a total of 463 patients with sepsis and/or septic shock. Overall, compared with standard treatment, esmolol significantly decreased 28-day mortality (risk ratio [RR] 0.68, 95% confidence interval [CI] 0.52 to 0.88), and heart rate (standardized mean difference [SMD] -1.83, 95% CI -2.95 to -0.70) and troponin I (TnI) level (SMD − 0.59, 95% CI -1.02 to -0.16) at 24 hours after treatment; no significant effect was found on the length of intensive care unit stay, mean arterial pressure, central venous pressure, central venous oxygen saturation, Stroke Volume Index, tumor necrosis factor-a, interleukin 6, White Blood Cells and PO2/FiO2. Conclusions Esmolol treatment may be safe and effective in decreasing 28-day mortality, controlling heart rate, and preventing myocardial damage, but no evidence of effect on lung injury in sepsis and septic shock after fluid resuscitation early. There were no significant adverse effects on tissue perfusion and oxygen utilization.

Association of polyunsaturated fatty acids with improved heart rate variability and cardiovascular events in patients with end-stage renal disease receiving maintenance dialysis: a systematic review and meta-analysis of randomized controlled trials

2021 ◽  
Author(s):  
Chu-Lin Chou ◽  
Jin-Shuen Chen ◽  
Yi-No Kang ◽  
Yuan-Jen Chen ◽  
Te-Chao Fang
Keyword(s):  
Systematic Review ◽  
Heart Rate ◽  
End Stage Renal Disease ◽  
Cardiovascular Events ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Maintenance Dialysis ◽  
Stage Renal Disease ◽  
End Stage

Objective: Apart from dietary restriction and medical therapy, the benefits of cardiovascular protection offered by polyunsaturated fatty acid (PUFA) supplements in patients with ESRD receiving maintenance dialysis remain unclear.

Sign in / Sign up

Export Citation Format

Share Document